Double-blind, placebo-controlled safety and efficacy trial with yohimbine hydrochloride in the treatment of nonorganic erectile dysfunction.

摘要: This double-blind, placebo-controlled clinical trial of yohimbine hydrochloride included 86 patients with erectile dysfunction and without clearly detectable organic or psychologic causes. The patient group fulfilled all entry criteria; 85 these could be considered for the Safety-respectively 83 Intention-to-treat (ITT)-analysis. Yohimbine was administered orally in a dosage 30 mg day (two 5 tablets three times daily) eight weeks. Patients were seen follow-up after four weeks' treatment, final visit Efficacy evaluation based on both subjective objective criteria. Subjective criteria improvement sexual desire, satisfaction, frequency contacts, quality erection (penile rigidity) during contact/intercourse. Objective outcome penile rigidity determined by use polysomnography sleep laboratory. Overall found significantly more effective than placebo terms response rate: 71 vs 45%. well-tolerated: Only 7% rated tolerability fair poor, most adverse experiences mild. There no serious event.